Avtor/Urednik | Strojan, Primož; Budihna, Marjan; Šmid, Lojze; Svetic, Branka; Vrhovec, Ivan; Kos, Janko; Škrk, Janez | |
Naslov | Cysteine proteinase inhibitors stefin A a106nd stefin B in operable carcinoma of the head and neck | |
Prevedeni naslov | Inhibitorji cisteinskih proteinaz stefin A in stefin B pri operabilnem karcinomu glave in vratu | |
Tip | članek | |
Vir | Radiol Oncol | |
Vol. in št. | Letnik 36, št. 2 | |
Leto izdaje | 2002 | |
Obseg | str. 145-51 | |
Jezik | eng | |
Abstrakt | Purpose. To evaluate the significance of cysteine proteinase inhibitors stefins (Stefs) A and B for a treatment decision and prognosis in operable squamous cell carcinoma of the head and neck (SCCHN). Patients and methods. Stefs A and B concentrations were determined immunobiochemically using ELISAs in cytosols prepared from the tumor and adjacent normal mucosa from 91 patients with operable SCCHN. The median follow-up period of patients alive at the close-out date was 5.8 years (range, 5-9.3 years). Results. Stef A concentrations were significantly higher in tumor compared to normal mucosa (FM.05). When a subgroup with clinically palpable nodes) at presentation was taken into consideration (n=57), a significant difference in Stef A (P=0.03) and Stef B (P=0.02) concentrations between those with negative and positive necks, as determined on histopathological examination, was observed. On the univariate survival analysis, higher Stefs' concentrations turned to be prognostically advantageous. Stef A proved its independent prognostic significance also on multivariate setting. Conclusions. With the capability to differentiate between the pN0- and pN+-stages of the disease in the patients originally presented as node-positive, Stefs A and B could be useful markers when deciding on the extent of neck surgery. In addition, both Stefs proved to be reliable prognosticators for survival in patients with operable SCCHN. | |
Izvleček | Namen. Ovrednotiti vlogo inhibitorjev cisteinskih proteinaz stefinov A in B v procesu odločanja o zdravljenju in njihov napovedni pomen pri operabilnem ploščatoceličnem karcinomu glave in vratu. Bolniki in metode. Koncentracije stefinov A in B so bile izmerjene imunobiokemično z uporabo ELISA testov v citosolih, pripravljenih iz tkiva tumorja in okolne zdrave sluznice 91 bolnikov z operabilnim ploščatoceličnim karcinomom glave in vratu. Ob zaključku opazovanega obdobja je znašal srednji čas spremljanja preživelih bolnikov 5,8 let (razpon 5-9,3 leta). Rezultati. Koncentracija stefina A je bila statistično pomembno višja v vzorcih tumorja kot v vzorcih zdrave sluznice (P=0.05). V skupini bolnikov s klinično tipnimi bezgavkami pred zdravljenjem (n=57) je bila ugotovljena signifikantna razlika v koncentracijah stefina A (P=0.03) in stefina B (P=0.02) med tistimi s histopatološko potrjeno prizadetostjo bezgavk in tistimi z neprizadetostjo vratnih bezgavk. V univariatni analizi preživetja so se kot prognostično ugodnejše izkazale visoke koncentracije stefinov. Stefin A je potrdil svoj neodvisen napovedni pomen tudi v multivariatni analizi. Zaključki. Kot dejavnika, zmožna razlikovati med patološkima stadijema bolezni pNo in pN+ pri bolnikih s klinično ugotovljeno prizadetostjo bezgavk, bi stefina A in B lahko vplivala na odločitev o obsegu operacije na vratu. Oba stefina sta se izkazala kot zanesljiva kazalca za napoved preživetja bolnikov z operabilnim ploščatoceličnim karcinomom glave in vratu. | |
Deskriptorji | HEAD AND NECK NEOPLASMS CARCINOMA, SQUAMOUS CELL CYSTEINE PROTEINASE INHIBITORS NEOPLASM STAGING DISEASE-FREE SURVIVAL |